Topics to be covered:
What do the political reforms of today mean for clinical research tomorrow?
Have the recently published draft regulations from the FDA (and the expected EMEA guidelines) addressed concerns about drug safety?
What can pharma/biotech companies do to continue to deliver innovative treatments in a cost effective way?
What can pharma/biotech learn from other regulated industries?
Expert Panalists:
Suzanne Gagnon, M.D.
Chief Medical Officer
ICON Clinical Research
Nigel Burrows
Senior Principal
IMS Health S.p.A.
Christopher - Paul Milne, D.V.M., M.P.H., J.D.
Associate Director - Tufts CSDD
Moderator
John W. Hubbard, Ph.D. FCP
Global President, ICON Clinical Research